Atypical hemolytic-uremic syndrome

MONDO:0016244

A rare, genetic thrombotic microangiopathy due to dysregulation of the alternative complement pathway and characterized by the triad of hemolytic anemia, thrombocytopenia, and acute renal dysfunction.

Also known as: Atypical Hemolytic Uremic Syndrome, D-HUS, aHUS, atypical HUS, atypical hemolytic uremic syndrome, hemolytic-uremic syndrome without diarrhea, hemolytic-uremic syndrome without diarrhoea, non-diarrhea-associated hemolytic uremic syndrome

65 clinical trials for this condition and its sub-types, 19 tagged with Atypical hemolytic-uremic syndrome itself.

Follow this condition to get notified about new trials

Where it sits in the disease tree

Browse by category →

Part of

↑ Syndromic disease (7158) ↑ Thrombotic microangiopathy (151) ↑ Complement deficiency (28) ↑ Hereditary hemolytic uremic syndrome (19)

Sub-types of Atypical hemolytic-uremic syndrome

Atypical hemolytic uremic syndrome with complement gene abnormality 0 trials
5 sub-types
Atypical hemolytic-uremic syndrome with DGKE deficiency 0 trials
Atypical hemolytic-uremic syndrome with H factor anomaly 0 trials
Atypical hemolytic-uremic syndrome with anti-factor H antibodies 0 trials

Including sub-types (65) Tagged with Atypical hemolytic-uremic syndrome (19)

Trials to join now! 9 Not yet recruiting 1 Not yet finished but already full! 4 Completed 4 Terminated 1

New drug aims to stop rare blood disorder in its tracks

Disease control Not yet recruiting

This Phase II trial tests a drug called NM8074 in 12 adults with atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots, low platelets, and kidney injury. The drug is given by IV infusion over several weeks. The goal is to see if NM8074 can bring bloo…

Phase 2 • Sponsor: NovelMed Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 12:06 UTC

Atypical hemolytic-uremic syndrome

Where it sits in the disease tree

New drug aims to stop rare blood disorder in its tracks